Biotech RadarJobs updated

COMPANY

AskBio

HQ: Durham, NC source · askbio.com ↗ · Southeast

Status: Acquired, now part of Bayer · How status works

Clinical Phase 2

4 open jobs · last seen Oct 23, 2026 · 10 sources

Keywords: late-onset pompe disease AAV Congestive Heart Failure Parkinson's Disease Parkinson Variant Multiple System Atrophy Parkinson Disease Limb Girdle Muscular Dystrophy Limb-Girdle Muscular Dystrophy Type 2 LGMD2I Muscular Dystrophy LGMD2 FKRP Mutation Fukutin Related Protein Heart Failure Ischemic Heart Disease Cardiovascular Diseases Systolic Heart Failure Heart Failure，Congestive Heart Arrhythmia Diastolic Heart Failure Multiple System Atrophy Pompe Disease (Late-onset) Pompe Disease Late-Onset AAV2-GDNF gene therapy AB-1003 3 x 10e13vg AB-1002 AB-1005 AB-1009 (GAA Gene) ACTUS-101 AB-1002

Profile checked Oct 10, 2026

4Open jobs9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Calibration TechnicianDurham, NCOct 19, 2026Oct 20, 2026
Senior Director, Biostatistics, Clinical Operations4 locations (listed on the posting)Oct 6, 2026Oct 8, 2026
Director, Pre-Clinical ManufacturingDurham, NCSep 23, 2026Oct 8, 2026
Manager, Data Management2 locations (listed on the posting)Sep 23, 2026Oct 8, 2026

See all 4 jobs

Timeline

  1. Trial start Phase 2: Prescriptive Infusion Algorithm (PIA) source ↗
  2. Board tracked Radar started tracking this company’s job board (4 open jobs at last check). source ↗
  3. Trial start Phase 1/Phase 2: A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD) source ↗
  4. Trial start —: AB-1005 Long-Term Follow-up Study source ↗
  5. Trial start Phase 2: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) source ↗
  6. Trial start Phase 2: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure source ↗
  7. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) source ↗
  8. Trial start —: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy source ↗
  9. Trial start Phase 1: AB-1002 in Patients With Class III Heart Failure source ↗
  10. Trial start Phase 1: AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 4

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Calibration TechnicianDurham, NCOct 19, 2026Oct 20, 2026Not stated
Senior Director, Biostatistics, Clinical Operations4 locations (listed on the posting)Oct 6, 2026Oct 8, 2026Senior
Director, Pre-Clinical ManufacturingDurham, NCSep 23, 2026Oct 8, 2026Senior
Manager, Data Management2 locations (listed on the posting)Sep 23, 2026Oct 8, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Phase 2Active, not recruitingJun 11, 2024Aug 31, 2028 (estimated)
NCT05230459A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)Phase 1/Phase 2Active, not recruitingMay 15, 20232028-12 (estimated)
NCT04179643AB-1002 in Patients With Class III Heart FailurePhase 1CompletedNov 20, 2019Aug 20, 2024 (actual)
NCT07215403Prescriptive Infusion Algorithm (PIA)Phase 2Not yet recruiting2026-11Apr 30, 2028 (estimated)
NCT05699460Pre-Gene Therapy Study in Parkinson's Disease and Multiple System AtrophyNot listedCompletedSep 29, 2022Nov 4, 2025 (actual)
NCT07282847A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)Phase 1/Phase 2RecruitingApr 15, 20262028-09 (estimated)
NCT03533673AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe DiseasePhase 1CompletedDec 17, 2018Sep 30, 2022 (actual)
NCT05598333Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailurePhase 2Active, not recruitingOct 20, 2023Oct 31, 2026 (estimated)
NCT07081841AB-1005 Long-Term Follow-up StudyNot listedEnrolling by invitationSep 4, 2025Sep 30, 2037 (estimated)

Connect

See your connections at AskBio on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback